CENTER FOR DRUG EVALUATION AND RESEARCH APPROVAL PACKAGE FOR:

APPLICATION NUMBER 19-676/S-016

Correspondence

Genentech. Inc.

1 DMA 3.8. South San Francisco, CA 94080-4990 650+225-1000 FAX (650) 225-6000

April 11, 2000

John Jenkins, M.D., **Acting Director** Center for Drug Evaluation and Research Division of Metabolic and Endocrine Drug Products, HFD-510 Food and Drug Administration 5600 Fishers Lane Rockville, MD 20857

Subject: NDA 19-676, S-016

Nutropin® Pubertal Dosing Supplement Amendment to a Pending Application

Item 2 - Labeling

Item 4 - Chemistry, Manufacturing, and Controls

Environmental Assessment

Dear Dr. Jenkins:

Genentech, Inc. is submitting the enclosed information to our supplement S-016 to NDA 19-676 for the pubertal dosing regimen of Nutropin [somatropin (rDNA origin)] for injection). For the record, we are submitting an email sent on April 10, 2000 with the final redlined version of the package insert, a clean version of the package insert, and a fax sent to Ms. Enid Galliers on April 6, 2000, following her request for an Environmental Assessment for this supplement. A desk copy is provided in a black binder for Ms. Crystal King, P.D., M.G.A., Project Manager. The review copies have been placed in the appropriate colored binders.

An electronic archival copy of this submission on one CD has been submitted under separate cover to the CDER Central Document Room, according to the Guidance for Industry—Providing Regulatory Submissions in Electronic Format—General Considerations. Text is provided in Adobe Acrobat pdf format. John Jenkins, M.D. April 11, 2000 Page 2

For help or information concerning any technical issues associated with the CD or electronic documents, please contact Mr. Scott Moore at (650) 225-7137 or Mr. Jan Van Gelder at (650) 225-1558. Please contact Ms. Fiona Cameron, Senior Manager, at (650) 225-1818, by fax at (650) 225-1397, or by email at cameron.fiona@gene.com if you have any other questions regarding the content of the application. We look forward to working with you during your review of this information.

Sincerely,

Robert L. Garnick, Ph.D.

Vice President Regulatory Affairs

MILL

DEPARTMENT OF HEALTH AND HUMAN SERVICES FOOD AND DRUG ADMINISTRATION

APPLICATION TO MARKET A NEW DRUG, BIOLOGIC, OR AN ANTIBIOTIC DRUG FOR HUMAN USE

Form Approved: OMB No. 0910-0338 Expiration Date: April 30, 2000 See OMB Statement on page 2.

FOR	ENA	HEE	ONLY	
ryn	rua	USE	URLY	

APPLICATION NUMBER

(Title 21, Code of Federal Regulations, 314 & 601) APPLICANT INFORMATION NAME OF APPLICANT DATE OF SUBMISSION Genentech, Inc. April 11, 2000 FACSIMILE (FAX) Number (Include Area Code) (650) 225-1397 TELEPHONE NO. (Include Area Code) (650) 225-1202 APPLICANT ADDRESS (Number, Street, City, State, Country, ZIP Code or Mail Code, AUTHORIZED U.S. AGENT NAME & ADDRESS (Number, Street, City, State, and U.S. License number if previously issued): ZIP Code, telephone & FAX number) IF APPLICABLE 1 DNA Way South San Francisco, CA 94080-4990 PRODUCT DESCRIPTION NEW DRUG OR ANTIBIOTIC APPLICATION NUMBER, OR BIOLOGICS LICENSE APPLICATION NUMBER (fi previously issued) NDA 19-676, S-016 ESTABLISHED NAME (e.g., Proper name, USP/USAN name) PROPRIETARY NAME (trade name) IF ANY somatropin (rDNA origin) for injection Nutropin@ CHEMICAL/BIOCHEMICAL/BLOOD PRODUCT NAME (If any) CODE NAME (If any) recombinant human growth hormone DOSAGE FORM: STRENGTHS ROUTE OF ADMINISTRATION: lyophilized 5mg vial, 10mg vial subcutaneous injection (PROPOSED) INDICATION(S) FOR USE: growth failure due to a lack of endogenous growth hormone APPLICATION INFORMATION APPLICATION TYPE M NEW DRUG APPLICATION (21 CFR 314.50) ABBREVIATED APPLICATION (ANDA, AADA, 21 CFR 314.94) (check one) ☐ BIOLOGICS LICENSE APPLICATION (21 CFR part 601) IF AN NDA. IDENTIFY THE APPROPRIATE TYPE 507 X 505 (b) (1) 505 (b) (2) IF AN ANDA, OR AADA, IDENTIFY THE REFERENCE LISTED DRUG PRODUCT THAT IS THE BASIS FOR THE SUBMISSION Name of Drug TYPE OF SUBMISSION M AMENDMENT TO A PENDING APPLICATION ORIGINAL APPLICATION (check one) RESUBMISSION ☐ PRESUBMISSION ANNUAL REPORT ☐ ESTABLISHMENT DESCRIPTION SUPPLEMENT ☐ SUPAC SUPPLEMENT ☐ EFFICACY SUPPLEMENT LABELING SUPPLEMENT CHEMISTRY MANUFACTURING AND CONTROLS SUPPLEMENT OTHER REASON FOR SUBMISSION copies of email responses PROPOSED MARKETING STATUS (check one) PRESCRIPTION PRODUCT (Rx) OVER THE COUNTER PRODUCT (OTC) NUMBER OF VOLUMES SUBMITTED 1 THIS APPLICATION IS ☐ PAPER PAPER AND ELECTRONIC | ELECTRONIC ESTABLISHMENT INFORMATION Provide locations of all manufacturing, packaging and control sites for drug substance and drug product (continuation sheets may be used if necessary). Include name, address, contact, telephone number, registration number (CFN), DMF number, and manufacturing steps and/or type of testing (e.g. Final dosage form, Stability testing) conducted at the site. Please indicate whether the site is ready for inspection or, if not, when it will be ready. Genentech, Inc. 1 DNA Way South San Francisco, CA 94080-4990 Cross References (list related License Applications, INDs, NDAs, PMAs, 510(k)s, IDEs, BMFs, and DMFs referenced in the current application) IND

This	application contains the following items: (Check all that apply)	
	1. Index	
Х	2. Labeling (check one) Draft Labeling Final Printed Labeling -	
	3. Summary (21 CFR 314.50 (c))	
Х	4. Chemistry section	
	A. Chemistry, manufacturing, and controls information (e.g. 21 CFR 314.50 (d) (1), 21 CFR 601.2)	
	B. Samples (21 CFR 314.50 (e) (1), 21 CFR 601.2 (a)) (Submit only upon FDA's request)	
	C. Methods validation package (e.g. 21 CFR 314.50 (e) (2) (i), 21 CFR 601.2)	
	5. Nonclinical pharmacology and toxicology section (e.g. 21 CFR 314.50 (d) (2), 21 CFR 601.2)	
	6. Human pharmacokinetics and bioavailability section (e.g. 21 CFR 314.50 (d) (3), 21 CFR 601.2)	
	7. Clinical Microbiology (e.g. 21 CFR 314.50 (d) (4))	
	8. Clinical data section (e.g. 21 CFR 314.50 (d) (5), 21 CFR 601.2)	
	9. Safety update report (e.g. 21 CFR 314.50 (d) (5) (vi) (b), 21 CFR 601.2)	
	10. Statistical section (e.g. 21 CFR 314.50 (d) (6), 21 CFR 601.2)	
	11. Case report tabulations (e.g. 21 CFR 314.50 (f) (1), 21 CFR 601.2)	
	12. Case report forms (e.g. 21 CFR 314.50 (f) (2), 21 CFR 601.2)	
	13. Patent information on any patent which claims the drug (21 U.S.C. 355 (b) or (c))	
	14. A patent certification with respect to any patent which claims the drug (21 U.S.C 355 (b) (2) or (j) (2) (A))	
	15. Establishment description (21 CFR Part 600, if applicable)	-
	16. Debarment certification (FD&C Act 306 (k)(1))	
	17. Field copy certification (21 CFR 314.50 (k) (3))	
	18. User Fee Cover Sheet (Form FDA-3397)	-
	19. OTHER (Specify)	
l agree warning request includin 1. (2. E 3. L 4. I 5. F 6. F 7. L If this a product The da: Warnin	to update this application with new safety information about the product that may reasonably affect the statement of contraindications, gs. precautions, or adverse reactions in the draft labeling. I agree to submit safety update reports as provided for by regulation or as ted by FDA. If this application is approved, I agree to comply with all applicable laws and regulations that apply to approved applications, ng, but not limited to the following: Good manufacturing practice regulations in 21 CFR 210 and 211, 606, and/or 820. Biological establishment standards in 21 CFR Part 600. Labeling regulations in 21 CFR 201, 606, 610, 660 and/or 809. In the case of a prescription drug or biological product, prescription drug advertising regulations in 21 CFR 202. Regulations on making changes in application in 21 CFR 314.70, 314.71, 314.72, 314.97, 314.99, and 601.12. Regulations on Reports in 21 CFR 314.80, 314.81, 600.80 and 600.81. Local, state and Federal environmental impact laws. polication applies to a drug product that FDA has proposed for scheduling under the Controlled Substances Act I agree not to market the tuntil the Drug Enforcement Administration makes a final scheduling decision. ta and information in this submission have been review and, to the best of my knowledge are certified to be true and accurate. ig: a willfully false statement is a criminal offense, U.S. Code, title 18, section 1001.	
SIGNAT	TYPED NAME AND TITLE ROBERT L. Garnick, Ph.D. DATE V.P., Regulatory Affairs April 11, 2000)
	SS (Street, City, State, and ZIP Code) DNA Way, South San Francisco, CA 94080-4990 Telephone Number (650) 225-1202	
instruc inform	c reporting burden for this collection of information is estimated to average 40 hours per response, including the time for review tions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection ation. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reduction to:	n of
Paper Huber 200 In	i. Reports Clearance Officer work Reduction Project (0910-0338) t H. Humphrey Building, Room 531-H dependence Avenue, S.W. ngton, DC 20201 An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control number.	

LABELING SUPPLEMENT (PUBERTAL DOSING):
Nutropin[®] [somatropin (rDNA origin) for injection]

ITEM 2 NDA 19-676, S-016

2. LABELING: APRIL 11, 2000 AMENDMENT

TABLE OF CONTENTS

<u>Item</u>		Vol ^{Tab}	<u>Page</u>
		(labeling\	proposed.pdf)
April 10, 2000:	Genentech's Revisions to Package Insert Based on Comments from Dr. Jenkins	1 ⁽⁵⁾	1
. April 11, 2000:	Clean Package Insert	1 ⁽⁶⁾	31 _

Subject: Nutropin Revised Pubertal PI Date: Mon, 10 Apr 2000 18:08:18 -0700

From: Fiona Cameron <cameron2@gene.com>

Organization: Genentech, Inc.

To: Crystal King 301-827-6423 FAX 301-443-9282 <KINGC@cder.fda.gov>,

- malozowskis@cder.fda.gov, perlsteinr@cder.fda.gov

Nutropin NDA 19-676 S-016 Pubertal Dosing

Dear All:

Further to our conversation today, attached is a redlined version of the Nutropin package insert showing your requested changes.

We added the mean +/- SD for the mean last measured height for the two groups as requested. Although the mean heights are adjusted for sex and it states so in the text, it may not be clear to the reader whether these values are representative of males, females or some combination of both. The presentation of the mean difference avoids this issue. We look forward to your final decision on this point.

Please let me know as soon as possible whether you are in agreement with these changes, and we will then prepare the final CD for submission.

Best regards Fiona

Γ		Name: 19-676S016redlinedPI_10APR00.doc
]	Type: Winword File (application/msword)
-		Encoding:



LABELING SUPPLEMENT (PUBERTAL DOSING):
Nutropin® [somatropin (rDNA origin) for injection]

ITEM 4 NDA 19-676, S-016

4. CHEMISTRY: APRIL 11, 2000 AMENDMENT

TABLE OF CONTENTS

<u>Item</u>		Vol	<u>Page</u>
	•	(cm	c\environ.pdf,
April 6, 2000:	Fax to Ms. Enid Galliers with		
	Environmental Assessment	1 ⁽⁸⁾	1

Genentech, Inc. Genentech, Inc. Genentech, Inc. Genentech, Inc. Genentech, Inc.

1 DNA Way South San Francisco, CA 94080-4990 (650) 225-1000

To: Enid Galliers	To:
Fax: 301 443 9282	Fax:
Company: FDA	Company:
Dept: DMEDP	Dept:

From:

Fiona Cameron, Regulatory Affairs

Tel: (650) 225-1818 Fax: (650) 225-1397

Date:

4/6/00

Number of Pages:

(including this one)

Reference: Nutropin NDA 19-676, S-016 Pubertal Dosing Supplement

Dear Enid:

As you requested, attached is our Environmental Assessment for the Nutropin pubertal dosing submission. We are requesting a categorical exclusion.

Please let me know if you have any questions, and thanks for your help with this.

Best regards

Fiona Cameron

cameron2@gene.com

IMPORTANT CONFIDENTIALITY NOTICE

The documents accompanying this telecopy transmission contain confidential information belonging to Genentech which is legally protected. The information is intended only for the use of the individual or entity named below. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or the taking of any action in reliance on the contents of this telecopy information is strictly prohibited. If you have received this telecopy in error, please immediately notify us by telephone to arrange for return of the telecopied documents to us. Thank you.

NDA LABELING SUPPLEMENT (PUBERTAL DOSING):

ITEM 4

Nutropin® [somatropin (rDNA origin) for injection]

4.A.5 <u>Environmental Assessment</u>

DATE OF SUBMISSION

6 April 2000

NAME AND ADDRESS OF APPLICANT/PETITIONER

Genentech, Inc.

1 DNA Way

South San Francisco, CA 94080-4990

DESCRIPTION OF PROPOSED ACTION

As specified in regulation at 21 CFR Section 25.15(d), Genentech, Inc. states that this NDA supplement for the pubertal dosing regimen of Nutropin qualifies for a categorical exclusion from the Environmental Assessment (EA) requirement. Specifically, under 21 CFR Section 25.31(b), any action on an NDA, abbreviated application, application for marketing approval of a biologic product or a supplement to these applications is categorically excluded and ordinarily does not require the preparation of an EA or an Environmental Impact Statement if the action increases the use of the active moiety, but the estimated concentration of the substance at the point of entry into the aquatic environment will be below 1 part per billion.

Using the formula and guidelines provided in Section III.A.2. of the Guidance for Industry – Environmental Assessment of Human Drug and Biologics Applications (Revision 1, July 1998), Genentech has determined that the estimated concentration of the substance at the point of entry into the aquatic environment from use will be below 1 part per billion. To Genentech's knowledge, no extraordinary circumstances exist.

U.S. NDA: Nutropin[®]—Genentech, Inc.

lenentech, Inc.

1 DNA Way South San Francisco, CA 94080-4990 (650) 225-1000 FAX (650) 225-6000

March 30, 2000

John Jenkins, M.D.,
Acting Director
Center for Drug Evaluation and Research
Division of Metabolic and Endocrine Drug Products, HFD-510
Food and Drug Administration
5600 Fishers Lane
Rockville, MD 20857

Subject:

NDA 19-676, S-016

Nutropin[®] [somatropin (rDNA origin) for injection]

Amendment to a Pending Application—Pubertal Dosing Supplement

Item 2-Labeling

Dear Dr. Jenkins:

Genentech, Inc. is submitting the enclosed information to our supplement S-016 to NDA 19-676 for the pubertal dosing regimen of Nutropin [somatropin (rDNA origin) for injection]. For the record, we are submitting emails that have been sent to the reviewers during the package insert negotiations. We are also including the final version of both the redlined and clean package insert showing the new text. A complete desk copy of all the items is provided in a black binder for Ms. Crystal King, P.D., M.G.A., Project Manager. The review copies have been placed in the appropriate colored binders.

In addition, as a Phase IV commitment, Genentech agrees to provide the following updates for the four-year period following the commercial launch of the pubertal dose regimen:

NDA Annual Reports (Nutropin and Nutropin AQ)
 We will create a subsection of the NCGS update section and use this to report the number of patients receiving a dose greater than or equal to 0.4 mg/kg and discuss any other information available relevant to these patients.

19676-110 sub rer

- Periodic Safety Reports (Nutropin and Nutropin AQ)
 We will create a section that describes the spontaneous adverse event reports and the safety information from NCGS for patients receiving greater than or equal to 0.4 mg/kg dosing, and discusses the safety profile of these patients as compared to patients receiving doses of less than 0.4 mg/kg (excluding Turner Syndrome and Chronic Renal Insufficiency patients).
- Expedited Adverse Event Reports (Nutropin and Nutropin AQ)
 We will include an indication that the patient was being dosed at greater than or equal to 0.4 mg/kg at the beginning of the narrative of any relevant expedited adverse event reports, and will also include this information in the cover letter that accompanies each of these reports.

An electronic archival copy of this submission on one CD has been submitted under separate cover to the CDER Central Document Room, according to the Guidance for Industry—Providing Regulatory Submissions in Electronic Format—General Considerations. Text is provided in Adobe Acrobat PDF format.

For help or information concerning any technical issues associated with the CD or electronic documents, please contact Mr. Scott Moore at (650) 225-7137 or Mr. Jan Van Gelder at (650) 225-1558. Please contact Ms. Fiona Cameron, Senior Manager, at (650) 225-1818, by fax at (650) 225-1397 or by email at cameron.fiona@gene.com if you have any other questions regarding the content of the application. We look forward to working with you during your review of this information.

Sincerely,

Robert L. Garnick, Ph.D.

Vice President

Regulatory Affairs

Published

DEPARTMENT OF HEALTH AND HUMAN SERVICES FOOD AND DRUG ADMINISTRATION

APPLICATION TO MARKET A NEW DRUG, BIOLOGIC, OR AN ANTIBIOTIC DRUG FOR HUMAN USE

Form Approved: CMB No. 0010-0338 Expiration Date: April 30, 2000 See CMB Statement on page 2.

APPLICATION NUMBER

	ONL'

(Title 21, Code of Federal Regulations, 314 & 601)

ARRIVALE INFORMATION					
APPLICANT INFORMATION					
NAME OF APPLICANT			DATE OF SUBMISSION March 30, 2000		
Genentech, Inc.					
) 225-1202		Number (Include Area Code) (650) 225-1397		
APPLICANT ADDRESS (Number, Street, City, Sta and U.S. License number if previously issued):	ste, Country, ZIP Code or Mail Code,		U.S. AGENT NAME & ADDRESS (Number, Street, City, State thone & FAX number) IF APPLICABLE		
1 DNA Way South San Francisco, CA 94080-4990					
PRODUCT DESCRIPTION					
NEW DRUG OR ANTIBIOTIC APPLICATION NUM	MBER, OR BIOLOGICS LICENSE AF	PLICATION NUMBE	PR (If previously issued) NDA 19-676, S-016		
ESTABLISHED NAME (e.g., Proper name, USP/L SOMETTODIN (TDNA OFIGIN		ROPRIETARY NAM NULTODING	E (trade name) if ANY		
CHEMICAL/BIOCHEMICAL/BLOOD PRODUCTN recombinant human growt	IAME (Hany)		CODE NAME (If any)		
DOSAGE FORM lyophilized	STRENGTHS: 5mg vial, 10mg via	L	ROUTE OF ADMINISTRATION: SUCCULABOUS INJECTION		
(PROPOSED) INDICATION(S) FOR USE:					
growth failure due to a la	ick of endogenous gr	owth hormon	18		
APPLICATION INFORMATION	·		:		
PPLICATION TYPE heck one) INEW DRUG APPLICATION	ION (21 CFR 314.50)	BREVIATED APPLIC	CATION (ANDA, AADA, 21 CFR 314.84)		
, E BIOLOG	GICS LICENSE APPLICATION (21 C	R part 801)			
IF AN NDA, IDENTIFY THE APPROPRIATE TYPE TO 505 (b) (1) 505 (b) (2) 507					
IF AN ANDA, OR AADA, IDENTIFY THE REFERE Name of Drug	NCE LISTED DRUG PRODUCT THE Holder of Approved A	AT 18 THE BASIS FO Application	OR THE SUBMISSION		
TYPE OF SUBMISSION (Check one) ORIGINAL APPLIC	CATION AMENOMENT TO AR	ENDING APPLICATION	PESUBMISSION		
PRESUBMISSION ANNUAL	ASPORT ESTABL	SHMENT DESCRIPTIO	N SUPPLEMENT SUPAC SUPPLEMENT		
☐ EFFICACY SUPPLEMENT ☐ L	ABELING SUPPLEMENY	CHEMISTRY MANUFAC	CTURING AND CONTROLS SUPPLEMENT		
REASON FOR SUBMISSION CODIES OF	email responses				
PROPOSED MARKETING STATUS (check one)	PRESCRIPTION PRODUCT (tus 🗆 o	WER THE COUNTER PRODUCT (OTC)		
NUMBER OF VOLUMES SUBMITTED 1	THIS APPLICAT	ION IS PAPE	ER		
ESTABLISHMENT INFORMATION					
Provide locations of all manufacturing, packaging and control sites for drug substance and drug product (continuation sheets may be used if necessary). Include name, address, contact, telephone number, registration number (CFN), DMF number, and manufacturing steps and/or type of testing (e.g. Final desage form, Stability testing) conducted at the site. Please indicate whether the site is ready for inspection or, if not, when it will be ready.					
Genentech, Inc. 1 DNA Way South San Prancisco, CA 94080-4990			•		
Cross References (list related License A application)	pplications, INDs, NDAs, PMA	s, 510(k)s, IDEs, I	BMFs, and DMFs referenced in the current		
IND					

T	This application contains the following items: (Check all that apply)									
		1.	Index							
X	(2.	Labeling (check one)	🔯 Draft La	beling	Final	Printed Labeling			
		3.	Summary (21 CFR 31-	4.50 (c))					-	
		4.	Chemistry section							
			A. Chemistry, manufa	cturing, and controls in	nformation (e.g	. 21 CFR 31	4.50 (d) (1), 21 C	FR 601.2)		
			B. Samples (21 CFR	314.50 (e) (1), 21 CFF	601.2 (a)) (Si	abmit only up	on FDA's reques	t)		
			C. Methods validation	package (e.g. 21 CFF	314.50 (0) (2	(I), 21 CFR	601.2)			
		5.	Nonclinical pharmacol	ogy and toxicology sec	ation (e.g. 21 C	FR 314.50	d) (2), 21 CFR 60	01.2)		
		6.	Human pharmacokine	ics and bloavallability	section (e.g. 2	1 CFR 314.	30 (d) (3), 21 CFF	(601.2)		
		7.	Clinical Microbiology (e.g. 21 CFR 314.50 (d) (4))					
		8.	Clinical data section (.g. 21 CFR 314.50 (d)	(5), 21 CFR (301.2)				
		9.	Safety update report (e.g. 21 CFR 314.50 (d) (5) (vi) (b), 2	1 CFR 601.2)			
Г		10). Statistical section (e.g.	21 CFR 314.50 (d) (6), 21 CFR 6 01	.2)				
Γ		11	. Case report tabulation	s (e.g. 21 CFR 314.50	(f) (1), 21 CF	R 601.2)				
		12	. Case report forms (e.g	, 21 CFR 314.50 (f) (2), 21 CFR 601	.2)				
		13	. Patent information on	any patent which claim	is the drug (21	U.S.C. 355	(b) or (c))			
		14	. A patent certification v	ulth respect to any pate	ent which claim	ns the drug (21 U.S.C 355 (b)	(2) or (j) (2) (A))		
		15	. Establishment descrip	tion (21 CFR Part 600	, if applicable)					
		16	B. Debarment certification	n (FD&C Act 306 (k)(1))					
		17	7. Field copy certification	(21 CFR 314.50 (k) (3	3))					₹
	_	18	. User Fee Cover Shee	(Form FDA 3397)						_
		19). OTHER (Specify)							•
			ATION					•		
requinch	min(uesi ludir 1. (ed l led l lg. L Goo	pdate this application wo precautions, or adverse in by FDA. If this application but not limited to the follow dimanufacturing practice.	reactions in the draft is in is approved, I agree wing: a regulations in 21 CFI	beling. I agree to comply with R 210 and 211	to submit sa ali applicabi	lety update repor e laws and regula	ts as provided for by reg	julation of as	
	2. I	Biok Lah	ogical establishment sta eling regulations in 21 C	ndards in 21 CFR Pari IFR 201, 606, 610, 660	: 600.) and/or 809.					
1 .	4.	lo #	ne case of a prescription	drug or biological proc	duct, prescripti	on drug adv	ertising regulation	6 in 21 CFR 202.		
	5. 6.	Reg Reg	ulations on making char ulations on Reports in 2	nges in application in 2 11 CFR 314.80, 314.81	;1 CFH 314.70 , 600.80 and 6	, 314.71, 314 100.81.	4./2, 31 4.9 /, 314	.55, ANG DUT.12.		
1	7 1	1	al, state and Federal emication applies to a drug	vironmental impact law	/2.		der the Cosmoller	d Substances Act I scree	e not to market the	
ana	duc	t un	til the Drug Enforcement	Administration makes	e final schedu	iling decision	١.			
The	da	ta a	and information in this su a willfully false statemen	bmission have been re	rview and, to th	te best of my	r knowledge are d n. 1001.	ertified to be true and ac	curate.	
			E OF RESPONSIBLE OFFI					Garnick, Ph.D.	DATE	
	- (11:1					latory Affairs	March 30, 2000	
	DRE	SS	(Street, City, State, and ZII		<u> </u>			Telephone Number		
	1	DN	A Way, South Sa	n Francisco,	CA 9408	0-4990		(650) 225-120	2	
Ins	strud Ionni	ctior latic	porting burden for these, searching existing on. Send comments region to:	data enurces cetteri	ing and main	taining the	data needad. M	ng completing and tev	MANALLE INE COMECTIOL	u Oi
Pa Hu 20	aper uber 10 In	wor t H.	eports Clearance Officer ik Reduction Project (09: Humphrey Building, Ro bendence Avenue, S.W. on, DC 20201	10-0338) om 531-H	perso	n is not requ	not conduct or ired to respond to it displays a curr	o, a collection of	.	

Please DO NOT RETURN this form to this address.

LABELING SUPPLEMENT (PUBERTAL DOSING):

ITEM 1

Nutropin® [somatropin (rDNA origin) for injection]

NDA 19-676, S-016

1. INDEX: MARCH 30, 2000 AMENDMENT

Ite	<u>m</u>	Vol ^{TAB}
AP	PLICATION FORM 356h	1 ⁽¹⁾
CO	VER LETTER(cover.pdf)	1 ⁽²⁾
1.	INDEX(ndatoc.pdf)	1 ⁽³⁾
2.	LABELING(labeling\abeltoc.pdf)	1 ⁽⁴⁾

LABELING SUPPLEMENT (PUBERTAL DOSING):

Nutropin® [somatropin (rDNA origin) for injection]

ITEM 2 NDA 19-676, S-016

2. LABELING: MARCH 30, 2000 AMENDMENT

TABLE OF CONTENTS

<u>Item</u>		Vol ^{Tab}	Page proposed pdf)
February 10, 2000:	Clean and Redlined Package Inserts Showing Proposed Changes Updated to Reflect Final Report	1 ⁽⁵⁾	- 1 :
March 22, 2000:	FDA's Proposed Label Version	1 (6)	58
March 22, 2000:	Genentech's Revisions to Label Based on Discussion of March 22, 2000	1 ⁽⁷⁾	62
March 23, 2000:	Genentech's Revisions to Label Based on Dr. Perlstein's conversation with Dr. Ken Attie of March 23, 2000, and Phase IV Commitment Proposal	1 ⁽⁶⁾	66
March 24, 2000:	Genentech's Revisions to Label Based on Discussion of March 24, 2000 and ANCOVA Analyses	1 ⁽⁹⁾	69
March 29, 2000:	Genentech's Revisions to Label Based on Discussion of March 29, 2000	1(10)	76
March 30, 2000:	Clean and Redlined Final Package Insert	1(11)	80

Subject: Nutropin Pubertal Dosing Submission Q&A

Date: Thu. 10 Feb 2000 07:49:55 -0800

From: Fiona Cameron <cameron2@gene.com>

Organization: Genentech, Inc.

To: kingc@cder.fda.gov, perlsteinr@cder.fda.gov

Nutropin NDA 19-676, S-016

Responses to Questions asked By Dr. Perlstein on 1/28/00

Dear Dr. Perlstein and Crystal:

Attached are Genentech's responses to the questions Dr. Perlstein asked Ken Attie on 1/28/00 regarding our Nutropin pubertal dosing submission. The following files are attached:

Clinical.pdf - this contains the questions and enswers in a .pdf format.

196765016PI_09FZE00.doc - a marked up copy of the package insert in Word, showing revisions to the pubertal efficacy information (red text) which were inadevertently omitted from the November update submission, as well as the new BMD information which was recently approved (blue text).

196765016cleanPI_09FEB00.doc - a clean version of the package insert also in Word.

I propose that we send you our correspondence to this supplement via email, and then at the end of the process we can compile the electronic archival CD with all of the correspondence, similar to how we did it for Nutropin Depot. Please let me know if this is not acceptable.

I expect to have the responses to the questions Sue-Jane had by the end of this week.

Hope things are going well for you both - please let me know if there are any problems with this email.

Best regards

Fiona

Name: 19-676S016cleanPI_09FEB00.doc
Type: Winword File (application/msword)
Encoding:

Name: 19-676S016PI_09FEB00.doc
Type: Winword File (application/msword)
Encoding:

Name: 19-676S016PI_09FEB00.doc
Type: Winword File (application/msword)
Encoding:

Name: clinical.pdf
Type: Acrobat (application/pdf)
Encoding:

Subject: 19-676-016 labeling

Date: Wed, 22 Mar 2000 10:49:22 -0500 (EST)

From: "Crystal King 301-827-6423 FAX 301-443-9282" <KINGC@cder.fda.gov>

To: "Fiona Cameron" <cameron2@gene.COM>
CC: "Crystal King" <KINGC@cder.fda.gov>

Encrypted and Signed

Fiona:

Attached is our label version for discussion. Please call us at 2pm EST at 301-827-6434.

Thanks, Crystal

C:\MYDOCU~1\NDA\N19676\N19676\PUBERT~1\LABELING.DOC

Name: C:\MYDOCU~1\ND
Type: Winword File (appl Encoding:

Subject: Nutropin NDA 19-676, Pubertal Dosing Package Insert

Date: Wed. 22 Mar 2000 19:06:47 -0800

From: Fiona Cameron <cameron2@gene.com>

Organization: Genentech, Inc.

To: kingc@cder.fda.gov, malozowskis@cder.fda.gov, perlsteinr@cder.fda.gov,

wangs@cder.fda.gov, sahlroott@cder.fda.gov

Nutropin NDA 19-676, S-016, Pubertal Dosing

Dear All:

Attached for your review is our revised draft of the package insert based on our discussion today (changes shown in revisions mode). Please note the following:

Efficacy

Our proposed wording is provided for your consideration.

IGF-I Levels

We have proposed the weighted average method of making the statement about the number of patients who experienced IGF-I levels above normal. However, we are willing to discuss this further.

Patients Discontinuing from the Study
The number of patients listed as having discontinued because they were
satisfied with height is now given as 11 (revised from 9) in the 0.7
mg/kg/wk group. After a review of the listings, two patients were
identified as having cited this as the reason (in addition to other
reasons which were then given as the discontinuation reason in the
database). These additional two patients are as follows:

23-703 lists "PT & PARENT SATIS HT" (see page 7 of the email submission to Sue Jane Wang dated 2/10/00, file clinical2.pdf)

159-223 lists "PATIENT WISHES TO STOP THE GROWTH HORMONE THERAPY AS HE HAS REACHED QUITE A SUBSTANTIAL HEIGHT" (page 9, ibid)

We are confirming management approval of our Phase IV commitment proposal, and hope to confirm that in writing via email as requested tomorrow.

Please let me know if there are any problems with the attached file. Thanks for your help, and look forward to talking with you again on Friday.

Best regards

Fiona

Name: FromGNE032200.doc

Type: Winword File (application/msword)

Encoding:

Encrypted

and Signed

Subject: Nutropin Pubertal Dosing Supplement - PI Revisions

Date: Thu, 23 Mar 2000 19:06:59 -0800

From: Fiona Cameron <cameron2@gene.com>

Organization: Genentech, Inc.

To: Crystal King 301-827-6423 FAX 301-443-9282 <KINGC@cder.fda.gov>, malozowskis@cder.fda.gov, perlsteinr@cder.fda.gov, wangs@cder.fda.gov,

sahlroott@cder.fda.gov

Nutropin NDA 19-676, S-016 Pubertal Dosing

Dear All:

Further to Dr. Perlatein's telecon with Ken Attie today, we are providing some additional proposals for revisions to the pubertal dosing section of the Nutropin package insert, attached as a word document.

We are including our proposed Phase IV commitment in writing as requested, also as a word document.

We look forward to talking with you again tomorrow Friday at 1pm your time (please let me know if there are any changes to this time, as we can be flexible). We will call you at 301 827 6434.

Thanks and best regards Fiona

FromGNE032300.doc	Name: FromGNE032300.doc Type: Winword File (application/msword) Encoding: base64
	Nomes DubDhagaTVCmt dog

Name: PubPhaseIVCmt.doc

Type: Winword File (application/msword)

Encoding:

Encrypted

and Signed

Subject: Nutropin NDA 19-676 Pubertal Dosing Package Insert

Date: Fri, 24 Mar 2000 22:12:10 -0800

From: Fiona Cameron <cameron2@gene.com>

Organization: Genentech, Inc.

To: Crystal King 301-827-6423 FAX 301-443-9282 <KINGC@cder.fda.gov, malozowskis@cder.fda.gov, peristeinr@cder.fda.gov, wangs@cder.fda.gov,

sahlroott@cder.fda.gov

Nutropin NDA 19-676 Pubertal Dosing Supplement 5-016

Dear All:

Further to our discussion today, attached are the following:

Revised Package Insert sections (FromGNE032400.doc)

Additional statistical information on ANCOVA analyses for Dr. Sahlroot (ANCOVAdata.doc)

Regarding the request for medians, below is information regarding percentage of IGF-I measurements above the normal range for individuals at various percentiles:

	0.3	0.7
25%ile	0%	0%
50%110	0 🔏	17%
75%ile	14 %	444

Look forward to talking to you again at ~11.15am your time on Monday. Best regards
Fiona

ANCOVAdata.doc	, , , , , , , , , , , , , , , , , , , ,
	Encoding: base64

_		nGNE032400.doc
FromGNE032400.doc	Type: Win	word File (application/msword)
	Encoding:	

Subject: Nutropin Pubertal Dosing - PI Revision

Date: Wed, 29 Mar 2000 18:31:18 -0800

From: Fiona Cameron <cameron2@gene.com>

Organization: Genentech, Inc.

To: Crystal King 301-827-6423 FAX 301-443-9282 <KINGC@cder.fda.gov>, malozowskis@cder.fda.gov, perlsteinr@cder.fda.gov, wangs@cder.fda.gov,

sahiroott@cder.fda.gov

Nutropin NDA 19-676, S-013, Pubertal Dosing Supplement

Dear All:

Attached are the revisions to the package insert based on our discussions today. An explanation of some of the edits we made is provided below.

- 1. We added age to the table since being an intent to treat analysis, several subjects who discontinued early were quite young and we are showing height and not height SDS.
- 2. We used SD for mean last measured height because we feel this best describes the variance of the population in addition to being a parameter that prescribers are most familiar with. We would be willing to put the 95% CI in, although this was deleted elsewhere in the text.
- 3. The use of standardized height in the 2nd ANCOVA analysis gave us a meaningless result, probably because this introduces a lot of confounding information. We therefore ran the ANCOVA using just baseline height and adding sex as a second covariate, which best approximates the previous ANCOVA where baseline height was used and the results were reported by sex. The difference was statistically significant.

Please let us know when you would like to discuss this again. Best regards and thank you for your help Fiona

Name: From GNE032900.doc
Type: Winword File (application/msword)
Encoding:

Encrypted

and Signed

Subject: Nutropin NDA 19-676 Pubertal Final Label

Date: Thu, 30 Mar 2000 13:18:17 -0800

From: Fiona Cameron < cameron 2@gene.com>

Organization: Genentech, Inc.

To: Crystal King 301-827-6423 FAX 301-443-9282 <KINGC@cder.fda.gov>

Nutropin NDA 19-676, S-016 Pubertal Dosing Supplement

Dear Crystal:

Attached per your request are the following:

Clean version of the final package insert for Nutropin, including the pubertal dosing information that we sent to you on 3/29/00 (19676cleanPI_30MAR00)

Electronic copy of the cover letter containing our Phase IV commitment (19676finalcover.doc)

I will fax you the requested information (signed cover letter, ToCs, Final Label) later today.

Thanks again for your help Best regards Fiona

		19676finalcover.doc
19676finalcover.doc	Type:	Winword File (application/msword)
	Encoding:	

Name: 19-676S016cleanPI_30MAR00.doc
Type: Winword File (application/msword)
Encoding:

Genentech, Inc.

1 DNA 3/2. South San Éranol de l'OA 940<mark>80-4990</mark> FAX (651 000 b) 00

March 27, 2000

John Jenkins, M.D. Acting Director Center for Drug Evaluation and Research Division of Metabolic and Endocrine Drug Products, HFD-510 Food and Drug Administration 5600 Fishers Lane Rockville, MD 20857



Subject: NDA 19-676, S-016

Nutropin[®] [somatropin (rDNA origin) for injection]

Amendment to a Pending Application—Pubertal Dosing Supplement

Item 8 - Clinical Section

Item 11 - Case Report Tabulations

Item 19 - Other

Dear Dr. Jenkins:

Genentech, Inc. is submitting the enclosed information to our supplement S-016 to NDA 19-676 for the pubertal dosing regimen of Nutropin [somatropin (rDNA origin) for injection]. For the record, we are submitting emails that have been sent to the reviewers in response to their questions with respect to Items 8 and 11. We are also including complete information regarding investigator financial disclosure under Item 19. This section was inadvertently incomplete in the original submission submitted on June 11, 1999. A complete desk copy of all the items is provided in a black binder for Ms. Crystal King, P.D., M.G.A., Project Manager. The review copies have been placed in the appropriate colored binders.

An electronic archival copy of this submission on one CD has been submitted under separate cover to the CDER Central Document Room, according to the Guidance for Industry - Providing Regulatory Submissions in Electronic Format – General Considerations. Text is provided in Adobe Acrobat pdf format. John Jenkins, M.D. March 27, 2000 Page 2

For help or information concerning any technical issues associated with the CD or electronic documents, please contact Mr. Scott Moore at (650) 225-7137 or Mr. Jan Van Gelder at (650) 225-1558.

Please contact Ms. Fiona Cameron, Senior Manager, at (650) 225-1818, by fax at (650) 225-1397 or by email at cameron.fiona@gene.com if you have any other questions regarding the content of the supplement. We look forward to working with you during your review of this information.

Sincerely,

Robert L. Garnick, Ph.D.

Vice President Regulatory Affairs

DEPARTMENT OF HEALTH AND HUMAN SERVICES

FOOD AND DRUG ADMINISTRATION

APPLICATION TO MARKET A NEW DRUG, BIOLOGIC, OR AN ANTIBIOTIC DRUG FOR HUMAN USE

(Title 21, Code of Federal Regulations, 314 & 601)

Form Approved: OMB No. 0910-0338 Expiration Date: April 30, 2000 See OMB Statement on page 2.

EAR	ED.4		O## V	,
TUR	TUA	U2E	ONLY	

APPLICATION NUMBER

(Title 21, Code of Federal Fi	eguiations, 514 a 001/			
APPLICANT INFORMATION				
NAME OF APPLICANT		DATE OF SUBMISS	ION	
Genentech, Inc.			March 27, 2000	
TELEPHONE NO. (Include Area Code) (650) 225	-1202	FACSIMILE (FAX) N	lumber (Include Area Code) (65	0) 225-1397
APPLICANT ADDRESS (Number, Street, City, State, Country and U.S. License number if previously issued): 1 DNA Way South San Francisco, CA 94080-4990	ry, ZIP Code or Mail Code,		AGENT NAME & ADDRESS (Nun & FAX number) IF APPLICABLE	
PRODUCT DESCRIPTION				
NEW DRUG OR ANTIBIOTIC APPLICATION NUMBER, OR	BIOLOGICS LICENSE APPL	CATION NUMBER (If	previously issued) NDA 19	-676, S-016
ESTABLISHED NAME (e.g., Proper name, USP/USAN name somatropin (rDNA origin) for		PRIETARY NAME (IN	ide name) IF ANY	
CHEMICAL/BIOCHEMICAL/BLOOD PRODUCT NAME (# a recombinant human growth hor	ny)		CODE NAME (If any)	<u>.</u>
DOSAGE FORM: STRENG			UTE OF ADMINISTRATION: abcutaneous inject:	ion
(PROPOSED) INDICATION(S) FOR USE:				
growth failure due to a lack of	endogenous grow	th hormone		
APPLICATION INFORMATION				
APPLICATION TYPE (check one)	· —		ON (ANDA, AADA, 21 CFR 314.94	3)
	INSE APPLICATION (21 CFR : 505 (b) (1) ☐ 505		507	
IF AN ANDA, OR AADA, IDENTIFY THE REFERENCE LIST Name of Drug		IS THE BASIS FOR TH		
TYPE OF SUBMISSION ORIGINAL APPLICATION PRESUBMISSION ANNUAL REPORT	MAMENDMENT TO A PEND	DING APPLICATION MENT DESCRIPTION SUI	☐ RESUBMISSION PPLEMENT ☐ SUPAC SU	PPLEMENT
EFFICACY SUPPLEMENT LABELING S	UPPLEMENT CHI	EMISTRY MANUFACTURI	NG AND CONTROLS SUPPLEMENT	OTHER
REASON FOR SUBMISSION copies of email	responses			
PROPOSED MARKETING STATUS (check one)	PRESCRIPTION PRODUCT (Rx)	OVER	THE COUNTER PRODUCT (OTC)	
NUMBER OF VOLUMES SUBMITTED 1	THIS APPLICATION	IS PAPER	PAPER AND ELECTRONIC	ELECTRONIC
ESTABLISHMENT INFORMATION				
Provide locations of all manufacturing, packaging and control address, contact, telephone number, registration number (Conducted at the site. Please indicate whether the site is re	CFN), DMF number, and manuf	acturing steps and/or	ation sheets may be used if neces type of testing (e.g. Final dosage t	ssary). Include name, orm, Stability testing)
Genentech, Inc. 1 DNA Way South San Francisco, CA				
94080-4990 Cross References (list related License Application)	ins, INDs, NDAs, PMAs, 5	i10(k)s, IDEs, BMF	s, and DMFs referenced in ti	ne current
IND				

This	application contains the following items: (Check all that apply)
	1. Index
	2. Labeling (check one)
	3. Summary (21-CFR 314.50 (c))
	4. Chemistry section
	A. Chemistry, manufacturing, and controls information (e.g. 21 CFR 314.50 (d) (1), 21 CFR 601.2)
	B. Samples (21 CFR 314.50 (e) (1), 21 CFR 601.2 (a)) (Submit only upon FDA's request)
	C. Methods validation package (e.g. 21 CFR 314.50 (e) (2) (i), 21 CFR 601.2)
	5. Nonclinical pharmacology and toxicology section (e.g. 21 CFR 314.50 (d) (2), 21 CFR 601.2)
X	6. Human pharmacokinetics and bioavailability section (e.g. 21 CFR 314.50 (d) (3), 21 CFR 601.2)
	7. Clinical Microbiology (e.g. 21 CFR 314.50 (d) (4))
	8. Clinical data section (e.g. 21 CFR 314.50 (d) (5), 21 CFR 601.2)
	9. Safety update report (e.g. 21 CFR 314.50 (d) (5) (vi) (b), 21 CFR 601.2)
	10. Statistical section (e.g. 21 CFR 314.50 (d) (6), 21 CFR 601.2)
	11. Case report tabulations (e.g. 21 CFR 314.50 (f) (1), 21 CFR 601.2)
	12. Case report forms (e.g. 21 CFR 314.50 (f) (2), 21 CFR 601.2)
	13. Patent information on any patent which claims the drug (21 U.S.C. 355 (b) or (c))
	14. A patent certification with respect to any patent which claims the drug (21 U.S.C 355 (b) (2) or (j) (2) (A))
	15. Establishment description (21 CFR Part 600, if applicable)
	16. Debarment certification (FD&C Act 306 (k)(1))
	17. Field copy certification (21 CFR 314.50 (k) (3))
	18. User Fee Cover Sheet (Form FDA 3397)
X	19. OTHER (Specify)
l agree	FICATION to update this application with new safety information about the product that may reasonably affect the statement of contraindications,
	ps, precautions, or adverse reactions in the draft labeling. I agree to submit safety update reports as provided for by regulation or as led by FDA. If this application is approved, I agree to comply with all applicable laws and regulations that apply to approved applications,
includir	g, but not limited to the following:
	Good manufacturing practice regulations in 21 CFR 210 and 211, 606, and/or 820. Biological establishment standards in 21 CFR Part 600.
	abeling regulations in 21 CFR 201, 606, 610, 660 and/or 809. In the case of a prescription drug or biological product, prescription drug advertising regulations in 21 CFR 202.
5.	Regulations on making changes in application in 21 CFR 314.70, 314.71, 314.72, 314.97, 314.99, and 601.12.
-	Regulations on Reports in 21 CFR 314.80, 314.81, 600.80 and 600.81. Local, state and Federal environmental impact laws.
	pplication applies to a drug product that FDA has proposed for scheduling under the Controlled Substances Act I agree not to market the tuntil the Drug Enforcement Administration makes a final scheduling decision.
The da	ta and information in this submission have been review and, to the best of my knowledge are certified to be true and accurate.
	ng: a willfully false statement is a criminal offense, U.S. Code, title 18, section 1001.
SIGNA	TYPED NAME AND TITLE ROBERT L. Garnick, Ph.D. DATE V.P., Regulatory Affairs March 27, 2000
ADDRE	SS (Street, City, State, and ZIP Code) Telephone Number
	ONA Way, South San Francisco, CA 94080-4990 (650) 225-1202
	the first that a three three transfers is entirely to a second to a constant to the first transfers transfers to the first transfers transfers transfers to the first transfers to the first transfers transfers to the first transfers transfers transfers to the first transfers tr

Public reporting burden for this collection of information is estimated to average 40 hours per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to:

DHHS, Reports Clearance Officer Paperwork Reduction Project (0910-0338) Hubert H. Humphrey Building, Room 531-H 200 Independence Avenue, S.W. Washington, DC 20201 An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control number.

Please DO NOT RETURN this form to this address.

LABELING SUPPLEMENT (PUBERTAL DOSING):

ITEM 1

Nutropin[®] [somatropin (rDNA origin) for injection]

NDA 19-676, S-016

1. INDEX: MARCH 27, 2000 AMENDMENT

<u>lter</u>	<u>n</u>		Vol ^{TAB}
API	PLICATION FORM 356h	(356h.pdf)	1 ⁽¹⁾
CO'	VER LETTER	(cover.pdf)	1 ⁽²⁾
1.	INDEX	(ndatoc.pdf)	1 ⁽³⁾
8.	CLINICAL DATA	(clinical\clintoc.pdf)	1 ⁽⁴⁾
11.	CASE REPORT TABULATIONS	(crt\datasets\datatoc.pdf)	1(11)
19	INVESTIGATOR FINANCIAL DISCLOSURE	(other\financ pdf)	1 (13)

LABELING SUPPLEMENT (PUBERTAL DOSING): Nutropin® [somatropin (rDNA origin) for injection]

ITEM 8 NDA 19-676, S-016

8. CLINICAL DATA: MARCH 27, 2000 AMENDMENT

TABLE OF CONTENTS

<u>Item</u>		Vol ^{Tab}	<u>Page</u>
		(clinsta	at\clinical.pdf)
February 10, 2000:	Responses to Questions Asked by Dr. Perlstein on 1/28/00	1 ⁽⁵⁾	1
February 10, 2000:	Responses to Questions Asked by Sue-Jane Wang and Crystal King on 2/7/00	1 ⁽⁶⁾	54
February 18, 2000:	Additional Information Request from Sue-Jane Wang	1 ⁽⁷⁾	70
February 29, 2000:	Response to Sue-Jane Wang's Question Regarding Patients Who Reached Adult Height	1 ⁽⁸⁾	151
March 2, 2000:	Responses to Questions Asked by Dr. Perlstein on 2/25/00	1 ⁽⁹⁾	159
March 6, 2000:	Responses to Questions Asked by Dr. Perlstein on 3/3/00	1 ⁽¹⁰⁾	240

Subject: Nutropin Pubertal Dosing Submission Q&A

Date: Thu, 10 Feb 2000 07:49:55 -0800

From: Fiona Cameron <cameron2@gene.com>

Organization: Genentech, Inc.

To: kingc@cder.fda.gov, perlsteinr@cder.fda.gov

Nutropin NDA 19-676, S-016 Responses to Questions asked By Dr. Perlstein on 1/28/00

Dear Dr. Perlstein and Crystal:

Attached are Genentech's responses to the questions Dr. Perlstein asked Ken Attie on 1/28/00 regarding our Nutropin pubertal dosing submission. The following files are attached:

Clinical.pdf - this contains the questions and answers in a .pdf format.

19676S016PI_09FEB00.doc - a marked up copy of the package insert in Word, showing revisions to the pubertal efficacy information (red text) which were inadevertently omitted from the November update submission, as well as the new BMD information which was recently approved (blue text).

19676S016cleanPI_09FEB00.doc - a clean version of the package insert also in Word.

I propose that we send you our correspondence to this supplement via email, and then at the end of the process we can compile the electronic archival CD with all of the correspondence, similar to how we did it for Nutropin Depot. Please let me know if this is not acceptable.

I expect to have the responses to the questions Sue-Jane had by the end of this week.

Hope things are going well for you both - please let me know if there are any problems with this email.

Best regards

Fiona

<u>]19-676S01</u>	6cleanPI 09FEB00	Name: 19-676S016cleanPI_09FEB00.doc Type: Winword File (application/msword) Encoding:
<u>] 19-676S01</u>	6PI_09FEB00.doc	Name: 19-676S016PI_09FEB00.doc Type: Winword File (application/msword) Encoding:
	Name: clinical Type: Acroba Encoding:	.pdf t (application/pdf)



Encrypted

and Signed

Subject: Nutropin Pubertal Dosing - Sue Jane's Questions

Date: Thu, 10 Feb 2000 17:05:01 -0800

From: Fiona Cameron <cameron2@gene.com>

Organization: Genentech, Inc.

To: kingc@cder.fda.gov

Nutropin NDA 19-676 S-016 Pubertal Dosing

Dear Crystal:

Attached are the responses to the questions that you and Sue-Jane Wang discussed with me on 2/7/00. If you could forward these to Sue Jane I would be grateful. Two files are attached:

clinical2.pdf - contains the questions and responses in pdf format

disp380.xpt - a SAS transport file containing a patient disposition dataset

I hope that these address Sue Jane's questions, we had already prepared these responses when we got the request email from you today. If there is any further clarification needed, please let me know and we will provide whatever is needed.

Best regards Fiona

ঠিdisp:80.xpt	Name: disp380.xpt Type: application/x-sas-xport Encoding:	
clinical2.pdf	Name: clinical2.pdf Type: Acrobat (application/pd Encoding:	lf)

Genentech, Inc. Genentech, Inc. Genentech, Inc. Genentech, Inc. Genentech, Inc.

FAX COVER SHEET

Regulatory Affairs Department One DNA Way South San Francisco, CA 94080-4990 (650) 225-1915 TWX: 9103717168 FAX: (650) 225-1397

FAX NUMBER:

(301) 443-9282

DATE:

February 18, 2000

TO:

Crystal King, P.D., M.G.A

(301) 827-6423

FROM:

Shawn McLaughlin, M.B.A., Regulatory Affairs

(650) 225-1915

NUMBER OF PAGES:

68 (including this page)

IMPORTANT CONFIDENTIALITY NOTICE

The documents accompanying this telecopy transmission contain confidential information belonging to Genentech which is legally protected. The information is intended only for the use of the individual or entity named below. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or the taking of any action in reliance on the contents of this telecopy information is strictly prohibited. If you have received this telecopy in error, please immediately notify us by telephone to arrange for return of the telecopied documents to us. Thank you.

Dear Crystal:

Please reference our Nutropin[®] Supplement for Pubertal Dosing, NDA 19-676, S-016, and Sue-Jane Wang's 2/13/00 request for additional information. Attached is a copy of the information we FedEx'd to her this afternoon. She specifically requested that the information be sent directly to her, to arrive tomorrow.

As previously discussed, we will prepare and submit an update to the electronic, archival file for NDA 19-676, S-016 this coming week, which compiles all the most recent requests from review activities.

Best regards,

Shawn D. McLaughlin

Genior Associate
Regulatory Affairs

Genentech, Inc.

February 18, 2000

1 DNA Way South San Francisco, CA 94080-4990 (650) 225-1000 FAX: (650) 225-6000

Sue-Jane Wang, Ph.D.
Senior Statistician
Center for Drug Evaluation and Research
Food and Drug Administration
PKLN 9B07, HFD-715
5600 Fishers Lane
Rockville, MD 20857

Subject: NDA 19-676, S-016

Response to request for information

Dear Dr. Wang:

Reference is made to our Supplemental New Drug Application, NDA 19-676, S-016, for Nutropin[®] [somatropin (rDNA origin) for injection], submitted June 11, 1999, providing clinical data to support the addition of a higher pubertal dose for pubertal patients being treated for growth failure due to a lack of adequate endogenous growth hormone secretion. Additionally, the Final report for this study was submitted November 19, 1999. This document provides the additional information as specified in your February 13, 2000 request, and as discussed in our teleconference on February 16.

- (1) SAS dataset of disp380.xpt and prim380b.xpt, both with the extrapolation indicator (requirement of bone age to be extrapolated to the date of subjects' last measured height).
- (2) An annotated CRF with SAS variable names listed in the three files submitted (prim_380.xpt, sec_380.xpt, else_380.xpt) and those variables used for analyses in Section 5 up to 5.3 (p.29-p.46) of the NDA jacket 52.1.
- (3) Statistical analysis outputs along with statistical tests (not data listings) for Figures 1 to 8 in the text and Tables 3 to 7 in Appendix.

Enclosed is a paper copy of the document as well as a zip disk containing data files. As previously agreed upon by Ms. Crystal King, Project Manager, we will follow-up with submission of a compiled update to the archival electronic

supplement 19-676, S-016 that includes all the most recent responses for information.

We hope you find this information helpful and sufficient for your needs. If you require anything further, please contact me at (650) 225-1915, fax: (650) 225-1397, or internet: shawn@gene.com.

Sincerely,

Shawn D. McLaughlin

Senior Associate Regulatory Affairs

cc: Crystal King, P.D., M.G.A.

Subject: Re: [Fwd: Re: Nutropin Pubertal Dosing]

Date: Tue, 29 Feb 2000 14:26:49 -0800

From: Joyce Baptista

baptista@gene.COM>

Organization: Genentech, Inc.

To: WANGS@cder.fda.gov

CC: Peggy Wooster <wooster@gene.COM>, shawn@gene.COM, KINGC@cder.fda.gov, Fiona Cameron <cameron.fiona@gene.COM>, Scott Moore <moore.scott@gene.COM>, "attie.kenneth" <attie.kenneth@gene.COM>

Ms. Wang,

We spoke on a telecom not long ago regarding the Nutropin pubertal dosing submission. I am the statistician who worked on the interim report for M0380g. Your last email was forwarded to me. Attached is my response. I hope you find it helpful. If you have any questions please let us know.

Thank you.

JB

```
Peggy Wooster wrote:
```

```
> ----- Original Message -----
> Subject: Re: Nutropin Pubertal Dosing
> Date: Mon, 28 Feb 2000 11:52:31 -0500 (EST)
> From: "Sue Jane Wang 301-827-7435 FAX 301-827-5875" <WANGS@cder.fda.gov>
> To: "Fiona Cameron" <cameron.fiona@gene.COM>, "Peggy Wooster"
> <wooster.peggy@gene.COM>
> CC: "Shawn McLaughlin" <shawn@gene.COM>, "Crystal King"
> <KINGC@cder.fda.gov>
> Hi Fiona and Peggy,
> I just sent an email to Shawn and learned that he won't be in until
> March 1, 2000. So, I am forwarding the email to you both.
> If you have any questions, I can be reached at (301)827-3089.
> Thanks, Sue-Jane
> Subject: Re: Nutropin Pubertal Dosing
> Date: Mon, 28 Feb 2000 11:46:25 -0500 (EST)
> From: "Sue Jane Wang 301-827-7435 FAX 301-827-5875" <WANGS@cder.fda.gov>
> To: "Shawn McLaughlin" <shawn@gene.com>
> CC: "Crystal King" < KINGC@cder.fda.gov>
> Shawn,
> There were 13 subjects who reached the adult height.
> Please provide the following information today if possible.
> (1) patient IDs of these subjects.
> (2) sample size, mean, median, sd, range of baseline height and adult
> height for the low dose and high dose separately.
> Thanks,
```

Re: [Fwd: Re: Nutropin Pubertal Dosing]

> Sue-Jane

Name: Sue Jane Wang 2.doc

Type: Winword File (application/msword)

Encoding:

Download Status: Not downloaded with message

Subject: Nutropin Pubertal Dosing NDA 19-676 S-016 Q&A

Date: Thu, 02 Mar 2000 19:05:09 -0800

From: Fiona Cameron < cameron 2@gene.com>

Organization: Genentech, Inc.

To: kingc@cder.fda.gov, perlsteinr@cder.fda.gov

Nutropin NDA 19-676, S-016 Pubertal Dosing Responses to Questions asked by Dr. Perlstein on 2/25/00

Dear Dr. Perlstein and Crystal:

Attached are Genentech's responses to the questions Dr. Perlstein asked Ken Attie on 2/25/00 regarding our Nutropin pubertal dosing submission. The following files are attached:

clinical_3.pdf (Questions derived from telephone call and our responses)

Table_02.doc (Word table as requested, also provided as .pdf in response to Question 4)

Please let me know if you have any problems with these files. Thanks and best regards
Fiona

[] ali-i-al 2 - 46	Name: clinical_3.pdf Type: Acrobat (application/pdf)
	Encoding:

Name: Table_02.doc
Type: Winword File (application/msword)
Encoding:



Subject: Nutropin Pubertal Dosing NDA 19-676, S-016 Q&A

Date: Mon, 06 Mar 2000 18:36:10 -0800

From: Fiona Cameron <cameron2@gene.com>

Organization: Genentech, Inc.

To: kingc@cder.fda.gov, perlsteinr@cder.fda.gov

Dear Crystal and Dr. Perlstein: Attached below are Genentech's responses to two questions asked by Dr. Perlstein on 3/3/00. Best regards Fiona

Nutropin Pubertal Dosing Submission, NDA 19-676, S-016 Responses to Dr Perlstein's Questions from 3/3/00 Telecon

1. When were the pretreatment growth rate measurements performed?

Previous height and date measured were recorded on the screening visit Case Report Form, which stipulates "at least 6 months prior to enrollment" (refer to submission dated November 19, 1999, page 444). For the 97 subjects enrolled, the range of days from date of previous height measurement was actually 70 to 511 days (mean 296 days) which is close to the range used in the Nutropin Depot study of 60 to 425 days. For the 3 patients in the pubertal dosing study whose previous height date was less than 5 months, the previous growth rate was set to "missing" and hence n=94 for previous growth rate in Table 4 - Demographics and Baseline Characteristics of the November 19, 1999 submission, page 32. Annualized baseline growth rates were calculated.

2. Were patients with the following disorders/concomitant medications excluded from the study:
Diabetes mellitus
Hypothalamic pituitary tumors diagnosed within one year of enrollment Allergy to components of the drug
Known bleeding disorder
Current treatment with methylphenidate or cryptoheptadine

A review of the baseline adverse events patient listings indicates that no patients with diabetes mellitus or known bleeding disorders entered the trial. With respect to pituitary tumors, one of the exclusion criteria was "patient has a history of malignancy diagnosed and/or has been treated within the past year" (refer to screening CRF in the submission of November 19, 1999, page 443). Although allergy to components of the drug was not a specific exclusion criterion, no allergic reactions to the drug were noted. Patients being treated with methylphenidate (Ritalin®) or cyproheptadine (Periactin®) were permitted to be included in the study, as many adolescents are treated with these drugs and this facilitated recruitment.



248

rech, Inc.

REC'D

NOV 2 2 1999

CDR

TON AND RES

CA 94080-4990

November 19, 1999

Solomon Sobel, M.D.
Director
Division of Metabolic and
Example Endocrine Drug Products, HFD-510
Center for Drug Evaluation and Research
Food and Drug Administration
Attn: Document Control Room, 148-03



뿐요 Subject: NDA 19-676, S-016

5600 Fishers Lane Rockville, MD 20857

Nutropin[®] [somatropin (rDNA origin) for injection] Labeling Supplement – Pubertal Dosing

Safety Update/Final Report

Dear Dr. Sobel:

Reference is made to our Supplemental New Drug Application, NDA 19-676, S-016, for Nutropin® [somatropin (rDNA origin) for injection], submitted on June 11, 1999, providing clinical data to support the addition of a higher dose for pubertal patients being treated for growth failure due to a lack of adequate endogenous growth hormone secretion. In accordance with 21 CFR 314.50(d)(5)(vi)(b), this submission provides the "four month" safety update. In addition, this submission contains Patent Information (Item 13) and Patent Certification (Item 14), which was not included in the original supplement, but was subsequently requested by the Agency.

As agreed to in a telephone conversation with Ms. Crystal King, FDA Project Manager, on September 15, 1999, the Final Report for study M0380g: A Phase III, Randomized, Multicenter Study of Nutropin Treatment at Two Dosage Levels In Pubertal Children with GHD, is being submitted as the Safety Update for this labeling supplement.

Solomon Sobel, M.D. November 19, 1999 Page 2

As this is a final report, both the efficacy and safety sections have been updated to include complete data for the study. As such, all sections of the interim report, submitted with the original application NDA 19-676, S-016, can be considered superseded by this final report. Since the major efficacy outcomes are essentially the same as discussed in the interim report, this is not intended as a submission of new efficacy data, as discussed with Ms. King.

Please note that in a few instances, the number of subjects with certain adverse events are less compared to the interim report. These changes are due to the following corrections to the database: 1) Four subjects with added baseline information resulting in event no longer being emergent. 2) Two subjects with correction of AE severity resulting in no change from baseline. 3) One subject with corrected mapping of AE to COSTART term. 4) One subject with correction (deletion) of AE.

This submission does not contain revised labeling, as the data collected during the update period is consistent with that seen earlier in the trial, and with the current draft labeling.

An electronic archival copy of this submission on CD-ROM has been submitted to the CDER Central Document Room, according to the Guidance for Industry-Providing Regulatory Submissions in Electronic Format- General Considerations. Text is provided in Adobe Acrobat pdf format. Patient listings and datasets are provided in electronic form only. The CD has been checked for computer viruses using Norton AntiVirus for Windows NT Workstation 5.01.01a (with virus definitions dated 9/22/99), and is hereby certified to be virus-free.

Should you have any further questions regarding this submission please contact Mr. Shawn McLaughlin of my staff at (650) 225-1915.

Sincerely,

Robert L. Garnick, Ph.D.

Vice President Regulatory Affairs


MILL

DUPLICATE

Genentech, Inc.

SUPPL NEW CORRESP

August 11, 1999



Solomon Sobel, M.D.


Director

Division of Metabolic and
Endocrine Drug Products, HFD-510

Center for Drug Evaluation and Research
Food and Drug Administration

Attn: Document Control Room, 14B-03

5600 Fishers Lane



Subject:

NDA 19-676, S-016

Nutropin[®] [somatropin (rDNA origin) for injection]

Labeling Supplement - Pubertal Dosing

Request for Waiver of Requirement to Conduct Pediatric Studies

[21CFR 201.23(a)]

Dear Dr. Sobel:

Rockville, MD 20857

Reference is made to our Supplemental New Drug Application, NDA 19-676, S-016, for Nutropin[®] [somatropin (rDNA origin) for injection], submitted on June 11, 1999 providing clinical data to support the addition of a higher pubertal dose for pubertal patients being treated for growth failure due to a lack of adequate endogenous growth hormone secretion.

Further to a telephone conversation with Crystal King of your office, and in regard to the FDA Final Rule: Regulations Requiring Manufacturers to Assess the Safety and Effectiveness of New Drugs and Biological Products in Pediatric Patients, we are requesting a waiver from the requirements of 21CFR 201.23(a), under subpart (c)(1), on the basis that adequate pediatric studies have already been performed with Nutropin.

Solomon Sobel, M.D. August 11, 1999 Page 2

The studies already performed in pediatrics include:

- Studies 86-061 and 87-070 in NDA 19-676, for pediatric growth hormone deficiency.
- Studies 87-069, M0079g, and M0221g in NDA 20-168, for growth failure associated with chronic renal insufficiency.
- Study 85-044 in NDA 20-656, for short stature associated with Turner syndrome.
- Study M0380g in IND for pubertal dosing in pediatric growth hormone deficiency.
- Phase IV study

Sincerely,

Robert L. Garnick, Ph.D.

Vice President

Regulatory Affairs

DEPARTMENT OF HEALTH AND HUMAN SERVICES

FOOD AND DRUG ADMINISTRATION

Form Approved: OMB No. 0910-0338 Expiration Date: April 30, 2000 See OMB Statement on last page.

APPLICATION NUMBER

APPLICATION TO MARKET A NEW DRUG, BIOLOGIC, OR AN ANTIBIOTIC DRUG FOR HUMAN USE

FOR FDA USE ONLY

(Title 21, Code of Federal Regulations, 314 & 601)

	 						
APPLICANT INFO	RMATION						
NAME OF APPLICANT			DATE OF SU	BMISSION			
Genentech, Inc	•		August 11, 1999				
TELEPHONE NO. (Includ		25-1202	FACSIMILE (FAX) Number (Include Area Code) (650) 225-1397				
APPLICANT ADDRESS U.S. License number if pre	(Number, Street, City, State, Country		JTHORIZED U.	S. AGENT NAME & ADDRESS (No	mber, Street, City, State,		
1 DNA Way	victory isobety.	21	r Code, releptions	• & FAX number) IF APPLICABLE			
•	cisco, California, USA	94080-4990					
License 1048							
PRODUCT DESCR	IPTION						
NEW DRUG OR ANTIBI	OTIC APPLICATION NUMBER	, OR BIOLOGICS LICENSE	APPLICATION	NUMBER (If previously issued) ND	A 19-676, S-016		
ESTABLISHED NAME (e.	g., Proper name, USP/USAN nam		PROPRIETARY	Y NAME (trade name) IF ANY			
somatropin (rDNA origi	<u>n) for injection</u> AL/BLOOD PRODUCT NAME (1)	l envi	Nutropin®	CODE NAME (If any)			
recombinant human gr	owth hormone			CODE NAME (II any)	+		
DOSAGE FORM: lyophilized	STRENG 5mg vial,			ROUTE OF ADMINISTRATION: subcutaneous injection	-		
(PROPOSED) INDICATION	ON(S) FOR USE:				-		
growth failure due to a	lack of endogenous growth he	ormone					
PLICATION INF	ORMATION						
PPLICATION TYPE	NEW DRUG APPLICATION (2	01 CER 214 50)	DDDE\//ATED.A	APPLICATION (ANDA, AADA, 21CF	B 214 04)		
(check one)		·		TELON ION (ANDA, ANDA, 21CE)	n 314. 34)		
		LICENSE APPLICATION (21			· · · · · · · · · · · · · · · · · · ·		
IF AN NDA. IDENTIFY TH			5 (b) (2)	□ 507	·		
Name of Drug	DENTIFY THE REFERENCE LI	Holder of Approved Ap		S FOR THE SUBMISSION			
TYPE OF SUBMISSION (check one)	ORIGINAL APPLICATION	B AMENDMENT TO A P	ENDING APPLICA	ATION RESUBMIS	SION		
PRESUBMISSION	ANNUAL REPORT	ESTABLISHM	ENT DESCRIPT	ION SUPPLEMENT S	UPAC SUPPLEMENT		
EFFICACY SUP	PLEMENT LABELING S	UPPLEMENT CHEMIST	RY MANUFACTU	JRING AND CONTROLS SUPPLEMEN	T SOTHER		
REASON FOR SUBMISS Request for Waiver of F	ION Requirement to Conduct Pedia	tric Studies					
PROPOSED MARKETING	G STATUS (check one)	PRESCRIPTION PRODUCT (RX)	OVER THE COUNTER PRODUC	r (OTC)		
NUMBER OF VOLUMES	SUBMITTED 1	THIS APPLICATION IS	PAPER	PAPER AND ELECTRONIC	□ ELECTRONIC		
ESTABLISHMENT	INFORMATION						
address, contact, telephon	nufacturing, packaging and control e number, registration number (C ase indicate whether the site is rea	FN), DMF number, and manuf.	acturing steps an	tinuation sheets may be used if nece id/or type of testing (e.g. Final dosage	ssary). Include name, a form, Stability testing)		
GENENTECH, INC. 1 DNA WAY SOUTH SAN FRANCISC	- CO, CALIFORNIA 94080-4990						
ross References (list r plication)	elated License Applications, IN	IDs, NDAs, PMAs, 510(k)s, iD	Es, BMFs, and	DMFs refer referenced in the curr	ent		
			•				

This	ap	olication contains the following items: (Check all that apply)									
	1.	Index									
	2.	Labeling (check one)									
	3.	Summary (21 CFR 314.50 (c))									
	4.	Chemistry Section									
		A. Chernistry, manufacturing, and controls information (e.g. 21 CFR 314.50 (d) (1), 21 CFR 601.2)									
		B. Samples (21 CFR 314.50 (e) (1), 21 CFR 601.2 (a)) (Submit only upon FDA's request)									
	C. Methods validation package (e.g. 21 CFR 314.50 (e) (2) (i), 21 CFR 601.2)										
	5. Nonclinical pharmacology and toxicology section (e.g. 21 CFR 314.50 (d) (2), 21 CFR 601.2)										
	6. Human pharmacokinetics and bioavailability section (e.g. 21 CFR 314.50 (d) (3), 21 CFR 601.2)										
	7. Clinical Microbiology (e.g. 21 CFR 314.50 (d) (4))										
	8.	Clinical data section (e.g. 21 CFR 314.50 (d) (5), 21 CFR 601.2)									
	9.	Safety update report (e.g. 21 CFR 314.50 (d) (5) (vi) (b), 21 CFR 601.2)									
	10.	Statistical section (e.g. 21 CFR 314.50 (d) (6), 21 CFR 601.2)									
	11.	Case report tabulations (e.g. 21 CFR 314.50 (f) (1), 21 CFR 601.2)									
	12.	Case reports forms (e.g. 21 CFR 314.50 (f) (2), 21 CFR 601.2)									
	13.	Patent information on any patent which claims the drug (21 U.S.C. 355 (b) or (c))									
	14.	A patent certification with respect to any patent which claims the drug (21 U.S.C. 355 (b) (2) or (j) (2) (A))									
	15.	Establishment description (21 CFR Part 600, if applicable)									
	16.	Debarment certification (FD&C Act 306 (k) (1))									
	17.	Field copy certification (21 CFR 314.5 (k) (3))									
	18.	User Fee Cover Sheet (Form FDA 3397)									
	19.	OTHER (Specify)									
warnings requeste including	bup, prod by 1. 2. 3. 4. 5. 6. 7. otical and	date this application with new safety information about the product that may reasonably affect the statement of contraindications, ecautions, or adverse reactions in the draft labeling. I agree to submit safety update reports as provided for by regulation or as FDA. If this application is approved, I agree to comply with all applicable laws and regulations that apply to approved applications, not limited to the following: Good manufacturing practice regulations in 21 CFR 210 and 211, 606, and/or 820. Biological establishment standards in 21 CFR Part 600. Labeling regulations in 21 CFR 201, 606, 610, 660, and/or 809. In the case of a prescription drug or biological product, prescription drug advertising regulations in 21 CFR 202. Regulations on making changes in application in 21 CFR 314.70, 314.71, 314.72, 314.97, 314.99, and 601.12. Regulations on reports in 21 CFR 314.80,314.81, 600.80 and 600.81. Local, state and Federal environmental impact laws. tion applies to a drug product that FDA has proposed for scheduling under the Controlled Substances Act I agree not to market the the Drug Enforcement Administration makes a final scheduling decision. Information in this submission have been reviewed and, to the best of my knowledge are certified to be true and accurate. willfully false statement is a criminal offense, U.S. Code, title 18, section 1001.									
. <i>// /</i>	4 -	OF RESPONSIBLE OFFICIAL OR AGENT TYPED NAME AND TITLE Robert L. Garnick, Ph.D., Vice President, Requistory Affairs August 11, 1999									
ADDRES		Street. City, State, and ZIP code)									
	1	DNA Way, South San Francisco, CA 94080-4990 (650) 225-1202									
instruction information	15, S In. 3	ting burden for this collection of Information is estimated to average 40 hours per response, including the time for reviewing earching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for burden to:									
perwor bert H.	k Re Hui endi	An agency may not conduct or sponsor, and a duction Project (0910-0338) person is not required to respond to, a collection of information unless it displays a currently valid OMB control number.									
		Please DO NOT RETURN this form to this address									

Genentech, Inc.

1 DNA Way South San Francisco, CA 94080-4990 (650) 225-1000 FAX: (650) 225-6000

June 24, 1999

Solomen Sobel, M.D.
Director
Division of Metabolic and
Endocrine Drug Products, HFD-510
Center for Drug Evaluation and Research
Food and Drug Administration
Attn: Document Control Room, 14B-03
5600 Fishers Lane
Rockville, MD 20857



Subject: N

NDA 20-522

Nutropin AQ® [somatropin (rDNA origin) injection]

Supplement - Labeling

Pubertal Dosing

Dear Dr. Sobel:

Reference is made to our New Drug Application, NDA 20-522, for Nutropin AQ[®] [somatropin (rDNA origin) injection], initially approved on December 29, 1995. As is reflected in the currently approved labeling, Nutropin AQ has been determined to be bioequivalent to lyophilized Nutropin[®], based on the statistical evaluation of AUC and C₋₋₋.

A supplement providing clinical data to support the addition of a higher pubertal dose for pubertal patients to the dosing section of the product insert has been submitted to NDA 19-676 (S-016, submitted June 11, 1999). This Nutropin supplement is therefore cross-referenced and the data contained therein is considered to be applicable to Nutropin AQ, based on the established bioequivalence of the two products. This revised labeling for Nutropin AQ is being submitted concurrently with the labeling supplement for lyophilized Nutropin in order to make possible a simultaneous review of the Pubertal Dosing supplements for both Nutropin and Nutropin AQ.

Solomon Sobel, M.D. June 24, 1999 Page 2

Enclosed is a revised package insert for Nutropin AQ* [somatropin (rDNA origin) injection] with the bone mineral density claim added. The changes are indicated by underlined text.

Should you have any questions regarding this submission please contact Mr. Shawn McLaughlin of my staff at (650) 225-1915.

Sincerely,

Robert L. Garnick, Ph.D.

Vice President Regulatory Affairs

put 1. Lh

DEPARTMENT OF HEALTH AND HUMAN SERVICES FOOD AND DRUG ADMINISTRATION

Form Approved: OMB No. 0910-0338 Expiration Date: April 30, 2000 See OMB Statement on last page.

APPLICATION TO MARKET A NEW DRUG, BIOLOGIC, OR AN ANTIBIOTIC DRUG FOR HUMAN USE

FOR FDA USE ONLY

(Title 21, Code of Federal Regulations, 314 & 601)

APPLICATION NUMBER

(Title 21, Code of Federal Regulations, 314 & 601)	
APPLICANT INFORMATION	
NAME OF APPLICANT	DATE OF SUBMISSION
Genentech, Inc.	June 24, 1999
TELEPHONE NO. (Include Area Code) (650) 225-1202	FACSIMILE (FAX) Number (Include Area Code) (650) 225-1397
APPLICANT ADDRESS (Number, Street, City, State, Country, ZIP Code or Mail Code, and U.S. License number if previously issued): 1 DNA Way South San Francisco, California, USA 94080-4990 License 1048	AUTHORIZED U.S. AGENT NAME & ADDRESS (Number, Street, City, State, ZIP Code, telephone & FAX number) IF APPLICABLE
PRODUCT DESCRIPTION	
NEW DRUG OR ANTIBIOTIC APPLICATION NUMBER, OR BIOLOGICS LICENS	E APPLICATION NUMBER (If previously issued) NDA 20-522
ESTABLISHED NAME (e.g., Proper name, USP/USAN name)	PROPRIETARY NAME (trade name) IF ANY Nutropin AQ®
somatropin (rDNA origin) injection CHEMICAL/BIOCHEMICAL/BLOOD PRODUCT NAME (# any) recombinant human growth hormone	CODE NAME (If any)
DOSAGE FORM: STRENGTHS:	ROUTE OF ADMINISTRATION:
Ilquid 10 mg viai (PROPOSED) INDICATION(S) FOR USE:	subcutaneous injection
growth failure due to a lack of endogenous growth hormone	
LICATION INFORMATION	
LICATION TYPE NEW DRUG APPLICATION (21 CFR 314.50)	☐ ABBREVIATED APPLICATION (ANDA, AADA, 21CFR 314.94)
BIOLOGICS LICENSE APPLICATION	(21 CFR part 601)
IF AN NDA, IDENTIFY THE APPROPRIATE TYPE 505 (b) (1)	505 (b) (2) 🔲 507
IF AN ANDA, OR AADA, IDENTIFY THE REFERENCE LISTED DRUG PRODUCT Name of Drug Holder of Approved	THAT IS THE BASIS FOR THE SUBMISSION Application
TYPE OF SUBMISSION (check one) ORIGINAL APPLICATION AMENDMENT TO	A PENDING APPLICATION B RESUBMISSION
D PRESUBMISSION DIANNUAL REPORT DI ESTABLE	SHMENT DESCRIPTION SUPPLEMENT
☐ EFFICACY SUPPLEMENT ☐ LABELING SUPPLEMENT ☐ CHE	MISTRY MANUFACTURING AND CONTROLS SUPPLEMENT
REASON FOR SUBMISSION To add additional pubertal dose to label	
PROPOSED MARKETING STATUS: (check one) # PRESCRIPTION PRODUCT	(Rx) OVER THE COUNTER PRODUCT (OTC)
NUMBER OF VOLUMES SUBMITTED 1 THIS APPLICATION IS	PAPER II PAPER AND ELECTRONIC II ELECTRONIC
ESTABLISHMENT INFORMATION	
Provide locations of all manufacturing, packaging and control sites for drug substance a address, contact, telephone number, registration number (CFN), DMF number, and miconducted at the site. Please indicate whether the site is ready for inspection or, if not,	enutacturing steps and/or type of testing (e.g. Hins/ dosage form, Statority (esting)
GENENTECH, INC. 1 DNA WAY SOUTH SAN FRANCISCO, CALIFORNIA 94080-4990	•
related License Applications, INDs, NDAs, PMAs, 510(k) (ication)	e, IDEs, BMFs, and DMFs refer referenced in the current
19-676, IND	•

This	ар	plication contains the follo	wing items: (C	check al	that apply)						
	1.	Index									
X	2.	Labeling (check one)	🖸 Draft	Labeling	☐ Final Printe	ed Labeling					
	3. Summary (21 CFR 314.50 (c))										
	 4. Chemistry Section A. Chemistry, manufacturing, and controls information (e.g. 21 CFR 314.50 (d) (1), 21 CFR 601.2) B. Samples (21 CFR 314.50 (e) (1), 21 CFR 601.2 (a)) (Submit only upon FDA's request) C. Methods validation package (e.g. 21 CFR 314.50 (e) (2) (i), 21 CFR 601.2) 5. Nonclinical pharmacology and toxicology section (e.g. 21 CFR 314.50 (d) (2), 21 CFR 601.2) 										
	6. Human pharmacokinetics and bioavailability section (e.g. 21 CFR 314.50 (d) (3), 21 CFR 601.2) 7. Clinical Microbiology (e.g. 21 CFR 314.50 (d) (4))										
	8.	Clinical data section (e.g. 2	1 CFR 314.50 (d) (5), 21	CFR 601.2) ITEM 8.E	: Phase I and II Final Reports					
	9.	Safety update report (e.g.	21 CFR 314.50	(d) (5) (vi) (b), 21 CFR 601.2)						
	10	. Statistical section (e.g. 21	CFR 314.50 (d)	(6), 21 (CFR 601.2)						
	11	. Case report tabulations (e.	g. 21 CFR 314.	50 (f) (1)	, 21 CFR 601.2)						
	12	2. Case reports forms (e.g. 2	1 CFR 314.50 (1) (2), 21	CFR 601.2)						
	13	3. Patent information on any	patent which cla	aims the	drug (21 U.S.C. 355 (b) o	or (c))	-				
	14	A patent certification with	respect to any p	atent wh	ich claims the drug (21.U	.S.C. 355 (b) (2) or (j) (2) (A))	•				
	15	. Establishment description	(21 CFR Part 6	00, if app	olicable)						
	16	6. Debarment certification (F	D&C Act 306 (k) (1))							
	17	7. Field copy certification (21	CFR 314.5 (k)	(3))							
	18	. User Fee Cover Sheet (Fo	m FDA 3397)								
	19). OTHER (Specify)			······································						
I agree warnin reques includii If this a produc The da	to up gs. po ted b ng. bi 1 2 3 4 5 6 7 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	recautions, or adverse reactions in by FDA. If this application is appro- ut not limited to the following: Good manufacturing practice re Biological establishment stands Labeling regulations in 21 CFR 1. Regulations on making changes Regulations on reports in 21 CFR 1. Local, state and Federal enviro	n the draft labeling, wed, I agree to cor guistions in 21 CFI rds in 21 CFR Par 201, 608, 610, 660 ig or biological pro- in application in 21 R 314.80,314.81, 6 nmental impact law it FDA has propose atton makes a fits ave been reviewed	. I agree to imply with a R 210 and t 600. , and/or 80 duct, preso I CFR 314 600.80 and ws. set for sche al schedulit and, to the	submit saféty update réports il applicable laws and regulation 211, 606, and/or 820. 9. Exiption drug advertising regulation, 314.71, 314.72, 314.97, 31600.81. Iduling under the Controlled Sing decision. The best of my knowledge are controlled services of my knowledge are controlled services.	14.99, and 601.12. ubstances Act I agree not to market the					
SIGNA		E OF RESPONSIBLE OFFICIAL	OR AGENT		NAME AND TITLE L. Gernick, Ph.D., Vice Pres	ident Bereinten Affelen	DATE June 24, 1999				
ADDRI		(Street, City, State, and ZIP code	,	noodit	L. GETRUG PROD., VICE PIEC	Telephone Number	1 00.004,1000				
	1	DNA Way, South S	an Francisc	o, CA	94080-4990	(650) 225	-1202				
instruct informa reducin	ions, ition. g this	searching existing data sources, or Send comments regarding this by burden to:	gathering and mair	ntaining the any other	data needed, and completing aspect of this collection of info	rmation, including suggestions for	-				
אופט _{ניט} pr. pr.	ork F H. Hi epeni	orts Clearance Officer Reduction Project (0910-0338) umphrey Building, Room 531-H dence Avenue, S.W. DC 20201		perso infor	gency may not conduct or spor in is not required to respond to nation unless it displays a cur ol number.	o, a collection of					

ORIGINAL

Genentech, Inc.

NDA NO. 19-676 REF NO. 016 NDA SUPPL FOR 5E2

LEME Was

Scutri San Francisco, CA 94080-4990

(650 | 225-1000 FAX | (650) 225-6000 June 11, 1999

Solomon Sobel, M.D.
Director
Division of Metabolic and
Endocrine Drug Products, HFD-510
Center for Drug Evaluation and Research
Food and Drug Administration
Attn: Document Control Room, 14B-03
5600 Fishers Lane
Rockville, MD 20857

Subject: NDA 19-676

Nutropin® [somatropin (rDNA origin) for injection]

Supplement—Labeling

Pubertal Dosing

REVIEWS COMPLETED

CSO ACTION:

LETTER | NA.L | MERCE

COOMETALS | DATE

Reference is made to our New Drug Application, NDA 19-676, for Nutropin[®] [somatropin (rDNA origin) for injection], approved on March 8, 1994 for treatment of growth failure due to a lack of endogenous growth hormone (GH). This submission provides a clinical data supplement to support the addition of a higher pubertal dose for pubertal patients to the dosing section of the product insert.

Genentech study M0380g, a Phase III, Randomized, Multicenter Study of Nutropin Treatment at Two Dosage Levels in Pubertal Children with GHD was undertaken to investigate the hypothesis that the replacement dose of growth hormone should be approximately doubled during puberty to emulate the physiologic increase normally seen at this time. The Division stated in a letter dated August 9, 1994 (copy included in this submission) that this single study will be sufficient to support this new dosing regimen. In this study, pubertal subjects were randomized to standard (0.3 mg/kg/wk) versus high dose (0.7 mg/kg/wk)

Dear Dr. Sobel:

Solomon Sobel, M.D. June 11, 1999 Page 2

GH and followed to near-adult height. Although standard GH therapy can result in mean adult heights within the normal range, adult heights are typically less than the respective target heights, possibly due to an inadequate pubertal growth spurt.

Adolescence is a time when GH and IGF-I levels are at their highest and sensitivity to GH is at its lowest. The objective of this study was to show that the higher dose is well tolerated, safe, and effective in improving adult height. Patients who were diagnosed or treated late, were inadequately treated, are far below the normal range for height, are growing poorly, have low IGF-I levels, or a combination of the above, may benefit from the relatively short course (2-5 years) of higher dose GH.

Adolescence is also a time of maximal bone mass accrual, coinciding with the time of maximal GH secretion. It has been shown that GH deficiency in childhood can reduce the peak bone mass attained, resulting in premature osteopenia or osteoporosis, despite GH replacement therapy. A secondary goal of the study is to determine the effect of GH dose during puberty on bone mineral density at the end of therapy. DEXA scan data will be summarized in the final report upon completion of the study.

Genentech proposes that the standard dose of 0.3 mg/kg/wk be recommended for all pediatric patients, but that a dose of up to 0.7 mg/kg/wk may be used in pubertal patients, at the discretion of the treating physician, and that IGF-I levels can be monitored to optimize dosing and avoid excess GH exposure. A paragraph describing study M0380g would also be included in the label.

This submission includes an interim report for study M0380g, at a point where approximately two-thirds of the subjects had reached near-adult height, based on the protocol-defined bone age criterion for treatment discontinuation. The primary endpoint specified in the protocol was "adult height", defined as epiphyseal fusion and no growth. In retrospect, it was unreasonable to expect most of these subjects to meet this criteria for quite some time, as evidenced by only a handful of subjects meeting the criteria at this time.

We elected to submit the data now based on the fact that over 80% of subjects had discontinued treatment and 66% achieved near-adult height. Because bone age progressed equally in both groups and was similar at baseline, the last measured heights could be used to compare the two dose groups.

Solomon Sobel, M.D. June 11, 1999 Page 3

An intent-to-treat analysis was also performed for all 97 subjects using the last measured heights. The analyses performed (ANCOVA) were as specified in the protocol. Since the magnitude of the difference between groups for the effect on adult height increases with continued treatment, the effects reported in this interim report are considered conservative with respect to the impact of the higher dose. Thus, we expect the final data from this study to show even greater gains in the high-dose group than that contained in the interim report.

In addition to improving near-adult height, the higher dose produced significant improvements in growth rate, height SDS, predicted height, and change in height, while having no adverse effect on the rate of pubertal progression or bone age advancement. The higher dose was in general not associated with an increased incidence of adverse events, confirming the known tolerability of higher GH and IGF-I levels in adolescents. Laboratory parameters including measures of glucose metabolism and antibodies to GH were likewise unaffected by the higher dose.

Genentech intends to file a safety update to this submission approximately four months after this submission, which should contain complete and final safety data for the study.

Two paper copies of this submission have been sent to the Agency, jacketed as clinical, and statistical review copies. A CD-ROM (containing the entire archival copy of the submission and relevant SAS datasets is also provided. Case Report Tabulations and Case Report Forms are submitted electronically only. This CD has been checked for computer viruses using Norton AntiVirus for Windows NT Workstation (with virus definitions dated 4/22/99), and is hereby certified to be virus-free.

We have enclosed a revised package insert for Nutropin[®] [somatropin (rDNA origin) injection] with our proposed changes added. The additions are indicated by underlined text, and include annotated references.

Solomon Sobel, M.D. June 11, 1999 Page 4

Should you have any questions regarding this submission please contact Mr. Shawn McLaughlin of my staff at (650) 225-1915.

Sincerely,

Robert L. Garnick, Ph.D.

Vice President Regulatory Affairs

nut!hl

This submission contains information that constitutes trade secrets and/or is confidential within the meaning of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. §331 [j]), the Freedom of Information Act (5 U.S.C. §552[b][4] and 18 U.S.C. Section 1905) and 21 CFR Sections 312.130, 314.430, 601.50, and 601.51 and may not be revealed or disclosed without the prior written authorization of Genentech, Inc.

Food and Drug Administration Rockville MD 20857

9029

RECEIVED

AUG 1 5 1994

REGULATORY AFFAIRS

Genentech, Inc. Attention: M. David MacFarlane, Ph.D. Vice President, Regulatory Affairs 460 Point San Bruno Boulevard South San Francisco, CA 94080

AUG 9 1994

Dear Dr. MacFarlane:

Please refer to your Investigational New Drug Application (IND) for Nutropin [somatropin (rDNA origin) for injection], IND

We also refer to your communication dated September 22, 1992, requesting input from the Division regarding the necessity of two clinical trials to support a new dosing regimen for growth hormone in pubertal children.

We further refer to your annual report dated April 20, 1994, which included, among other things, the same request (specifically, a request that you be provided, in writing, confirmation of the telephone conversation between Dr. Ursala Fritsch, of your office, and Ms. Lana Braithwaite (now Pauls) of this Division on August 17,1992, in which she indicated that only one clinical trial would be required.

We have completed our review of these submissions and have the following comments:

The single study, identified as M0380g, will be sufficient to support a new dosing regimen in pubertal children.

Should you have any questions, please contact Ms. Lana Pauls at (301) 443-3510.

Your cooperation is appreciated.

Sincerely yours,

Solomon Sobel, M.D.

Director

Division of Metabolism and

Endocrine Drug Products (HFD-510)

Center for Drug Evaluation and Research

DEPARTMENT OF HEALTH AND HUMAN SERVICES FOOD AND DRUG ADMINISTRATION

Form Approved: OMB No. 0910-0338 Expiration Date: April 30, 2000 See OMB Statement on last page.

APPLICATION NUMBER

APPLICATION TO MARKET A NEW DRUG, BIOLOGIC, OR AN ANTIBIOTIC DRUG FOR HUMAN USE

FOR FDA USE ONLY

(Title 21, Code of Federal Regulations, 314 & 601) APPLICANT INFORMATION-NAME OF APPLICANT DATE OF SUBMISSION June 11, 1999 Genentech, inc. FACSIMILE (FAX) Number (Include Area Code) TELEPHONE NO. (Include Area Code) 225-1202 (650)(650)225-1397 APPLICANT ADDRESS (Number, Street, City, State, Country, ZIP Code or Mail Code, and AUTHORIZED U.S. AGENT NAME & ADDRESS (Number, Street, City, State, U.S. License number if previously issued):

ZIP Code, telephone & FAX number) IF APPLICABLE 1 DNA Way South San Francisco, California, USA 94080-4990 License 1048 PRODUCT DESCRIPTION NEW DRUG OR ANTIBIOTIC APPLICATION NUMBER, OR BIOLOGICS LICENSE APPLICATION NUMBER (# previously insued) NDA 19-676 PROPRIETARY NAME (trade name) IF ANY ESTABLISHED NAME (e.g., Proper name, USP/USAN name) somatropin (rDNA origin) for injection CHEMICAL/BIOCHEMICAL/BLOOD PRODUCT NAME (# arry) **Nutropin®** CODE NAME (# any) recombinant human growth hormone DOSAGE FORM: STRENGTHS: **ROUTE OF ADMINISTRATION:** subcutaneous injection 5mg vial,10mg vial lyophilized (PROPOSED) INDICATION(S) FOR USE: growth failure due to a lack of endogenous growth hormone LICATION INFORMATION APPLICATION TYPE ABBREVIATED APPLICATION (ANDA, AADA, 21CFR 314.94) ■ NEW DRUG APPLICATION (21 CFR 314.50) (check one) TI BIOLOGICS LICENSE APPLICATION (21 CFR part 601) **505** (b) (1) 1 505 (b) (2) 507 IF AN NDA, IDENTIFY THE APPROPRIATE TYPE IF AN ANDA, OR AADA, IDENTIFY THE REFERENCE LISTED DRUG PRODUCT THAT IS THE BASIS FOR THE SUBMISSION Holder of Approved Application Name of Drug TYPE OF SUBMISSION II RESUBMISSION MENDMENT TO A PENDING APPLICATION (check one) ORIGINAL APPLICATION SUPAC SUPPLEMENT **ESTABLISHMENT DESCRIPTION SUPPLEMENT** ANNUAL REPORT PRESUBMISSION CHEMISTRY MANUFACTURING AND CONTROLS SUPPLEMENT **OTHER LABELING SUPPLEMENT** EFFICACY SUPPLEMENT REASON FOR SUBMISSION To add additional pubertal dose to jabel PROPOSED MARKETING STATUS (check one) **PRESCRIPTION PRODUCT (Rx)** OVER THE COUNTER PRODUCT (OTC) O PAPER PAPER AND ELECTRONIC **□** ELECTRONIC NUMBER OF VOLUMES SUBMITTED THIS APPLICATION IS ESTABLISHMENT INFORMATION Provide locations of all manufacturing, packaging and control sites for drug substance and drug product (continuation sheets may be used if necessary). Include name, address, contact, telephone number, registration number (CFN), DMF number, and manufacturing steps and/or type of testing (e.g. Final dosage form, Stability testing) conducted at the site. Please indicate whether the site is ready for inspection or, if not, when it will be ready. GENENTECH, INC. 1 DNA WAY SOUTH SAN FRANCISCO, CALIFORNIA 94080-4990 s References (list related License Applications, INDs, NDAs, PMAs, 510(k)s, IDEs, BMFs, and DMFs refer referenced in the current .cation) NDA 20-522, IND ---

This	ap	olication cont	ains the follo	wing items: (C	heck all t	hat apply)						
<u> </u>	1.	index pa	per/electron	ic		•		·		•		
<u> </u>	2.	Labeling (che	ck one)	Draft L	abeling		Final Printed L	abeling	paper/el	ectroni	c .	
	3.	Summary (21	CFR 314.50 ((c))								
	4.	Chemistry Se	ection									
		A. Chemistr	y, manuf <u>a</u> cturi	ng, and controls	information	on (e.g. 21 Cf	R 314.50 (d)	(1), 21 CF	R 601.2)			
		B. Samples	(21 CFR 314.5	50 (e) (1), 21 CF	R 601.2 (a	i)) (Submit on	ly upon FDA's	request)				
		C. Methods	validation pac	kage (e.g. 21 CF	R 314.50	(e) (2) (i), 21	CFR 601.2)					
	5.	Nonclinical p	harmacology a	and toxicology s	ection (e.g	. 21 CFR 314	.50 (d) (2), 21	CFR 601	.2)			
	6.	Human phan	nacokinetics a	and bioavailabilit	y section ((e.g. 21 CFR	314.50 (d) (3),	21 CFR	601.2)			
	7.	Clinical Micro	biology (e.g. 2	1 CFR 314.50 (d) (4))							
x	8.	Clinical data	section (e.g. 2	21 CFR 314.50	(d) (5), 21	CFR 601.2)	paper/elec	tronic				
	9.	Safety update	report (e.g. 2	1 CFR 314.50 (d) (5) (vi) ((b), 21 CFR 6	01.2)					
	10.	Statistical se	ction (e.g. 21 (CFR 314.50 (d)	(6), 21 CF	R 601.2)		·				
×	11.	Case report	tabulations (e.	g. 21 CFR 314.	50 (f) (1),	21 CFR 601.	2) electronic					
x	12.	Case reports	forms (e.g. 2	1 CFR 314.50 (f) (2), 21 C	FR 601.2)	electronic					
	13.	Patent inform	ation on any	patent which clai	ms the dr	ug (21 U.S.C.	355 (b) or (c))				
	14.	A patent cert	ification with n	espect to any pa	tent which	n claims the d	rug (21 U.S.C	355 (b)	(2) or (j) (2)	(A))		
	15.	Establishme	nt description (21 CFR Part 60	0, if applic	cable)			<u></u>	-		<u> </u>
· v	16.	Debarment of	ertification (F	D&C Act 306 (k) (1))	aper/electro	nic					
-	17.	Field copy ce	rtification (21	CFR 314.5 (k) (3))	·						
X	18.	User Fee Co	ver Sheet (Fo	rm FDA 3397)	paper/c	electronic						
X	19.	OTHER (S	pecify) Di	sciosure of fi	nancial	interests of	clinical in	estigate	ors (pape	r/electro	nic)	
CERTII	FICA	TION	 	ty information abou								
warning.	s, pre	ecautions, or adv	erse reactions in	the draft labeling. ed, I agree to com	agree to si	ubmit safety upo	late reports as pr	ovided for I	by regulation	or as		
	g, bul	not limited to the	following:	ulations in 21 CFR	-		-	.,,		•		
	2.	Biological estab	lishment standar	ds in 21 CFR Part of 1, 606, 610, 660, a	500.							
	4.	in the case of a	prescription drug	or biological produ n application in 21 (act, prescrip							
	6.	Regulations on r	eports in 21 CFR	314.80,314.81, 60 mental impact (swi	0.80 and 60				-			
	plica	tion applies to a d	trug product that	FDA has proposed tion makes a final	for schedu		ontrolled Substar	ces Actia	grée not to m	arket the		
The dat	a and	information in th	is submission ha	ve been reviewed a	and, to the b	est of my knowl	edge are certified	to be true	and accurate).		
			BLE OFFICIAL C			ME AND TITLE	· · · · · · · · · · · · · · · · · · ·				DATE	
*00005	00 //	1441L	<u></u>		Robert L.	Garnick, Ph.D.,	Vice President				June 11, 199	19
ADDRE		Street, City, State		an Francisco	. CA 9	94080-4990	1	Telephone	(650)	225-1	202	
Public r				of Information is e				, including	_`			
instructio	XIS, S	earching existing	data sources, ga	athering and maintander estimate or ar	ining the da	ta needed, and	completing and r	eviewing it	ne collection o	of .		
reducing	this I	burden to:	•				•		,			
		ns Clearance Of Eduction Project (•	person i	not required to	luct or sponsor, a respond to, a co	llection of				
inde	pende	mphrey Building, ence Avenue, S.V			informat control r		plays a currently	valid OME				
Washing	ton, [OC 20201		Please DO NOT	RETI ION	this form to thie	acidrace					
				. 10000 20 1401								



Food and Drug Administration Rockville MD 20857

NDA 19-676/S-016

JUN 28 1999

Genentech, Inc 1 DNA Way South San Francisco, CA 94080-4990

Attention: Robert L. Garnick, Ph.D.,

Vice, President, Regulatory Affairs

Dear Dr. Garnick:

We acknowledge receipt of your supplemental application for the following:

Name of Drug:

Nutropin[®] [Somatropin (rDNA origin) for Injection]

NDA Number:

19-676

Supplement Number:

S-016

Date of Supplement:

June 11, 1999

Date of Receipt:

June 14, 1999

Unless we find the application not acceptable for filing, this application will be filed under Section 505(b)(1) of the Act on August 13, 1999, in accordance with 21 CFR 314.101(a).

All communications concerning this NDA should be addressed as follows:

Center for Drug Evaluation and Research
Division of Metabolic and Endocrine Drug Products, HFD-510
Office of Drug Evaluation II
Attention: Document Control Room 14B-19
5600 Fishers Lane
Rockville, MD 20857

Enid Galliers

Chief, Project Management Staff
Division of Metabolic and Endocrine
Drug Products, HFD-510
Office of Drug Evaluation II
Center for Drug Evaluation and Research

NDA 19-676/S-016 Page 2

cc:

Original NDA 19-676/S-016 HFD-510/Div. Files HFD-510/CSO/C. King

filename: C:\WPFILES\19676ACK.WPD

SUPPLEMENT ACKNOWLEDGEMENT